UTAH MEDICAL PRODUCTS INC financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data UTAH MEDICAL PRODUCTS INC files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	39.3	41.4	42	46.9	42.2	49.1	52.3	50.2	40.9	38.5
Cost of revenue	15.6	15	15.7	17.4	16.6	18.1	20.1	20.2	16.8	16.5
Gross profit	23.7	26.4	26.3	29.5	25.5	30.9	32.2	30	24.1	22
Research and development	0.48	0.45	0.45	0.48	0.49	0.53	0.49	0.56	0.81	0.67
Selling and marketing	1.67	1.54	1.71	1.74	1.55	1.41	1.51	1.69	1.9	2.05
General and administrative	5.36	5.39	5.45	9.61	9.8	10.1	10.4	11	7.84	7.88
Operating income	16.2	19	18.7	17.6	13.7	18.9	19.8	16.8	13.6	11.4
Other non-operating income	0.13	-0.03	0.44	-0.01	0	0	0.19	0.26	-0.17	-0.12
Pre-tax income	16.4	19.1	19.5	17.9	13.8	19.1	20.7	20.1	16.8	14.1
Income tax	4.29	10.6	0.9	3.16	3.04	4.27	4.19	3.45	2.93	2.82
Net income	12.1	8.51	18.6	14.7	10.8	14.8	16.5	16.6	13.9	11.3
EBITDA	16.8	19.7	19.5	18.3	14.4	19.5	20.4	17.4	14.3	12.2
EPS, basic	3.23	2.29	4.97	3.96	2.95	4.05	4.53	4.58	3.96	3.48
EPS, diluted	3.22	2.28	4.95	3.94	2.94	4.04	4.52	4.57	3.96	3.48
Shares, basic (weighted)	3.75	3.72	3.73	3.72	3.66	3.65	3.64	3.63	3.5	3.24
Shares, diluted (weighted)	3.77	3.74	3.75	3.74	3.67	3.66	3.64	3.64	3.5	3.24

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	26.3	39.9	51.1	42.8	51.6	61	75.1	92.9	83	85.8
Receivables	3.21	3.62	3.96	4.74	4.1	5.13	5.54	3.39	4.09	3.52
Inventory	4.54	5.24	6.91	6.91	6.22	6.6	8.81	9.58	8.81	7.94
Other current assets	0.36	0.37	0.42	0.44	0.35	0.46	0.52	0.43	0.45	0.53
Total current assets	34.5	49.2	60.9	54.9	62.3	73.2	89.9	106	96.3	97.7
Property, plant and equipment	9.97	11.6	10.4	10.7	11.3	10.6	10.2	10.6	9.76	9.91
Lease right-of-use assets			0	0.41	0.38	0.45	0.4	0.34	0.34	0.29
Goodwill	13.5	14.1	13.7	14	14.2	14.1	13.4	13.7	13.6	14.1
Intangible assets	18.3	17.8	14.8	30.2	24	17.8	10.4	4.95	2.87	0.84
Total assets	76.2	92.7	99.8	110	112	116	124	135	123	123
Accounts payable	0.91	0.93	0.98	1.1	0.79	0.76	1.22	0.77	0.7	0.91
Accrued liabilities	2.12	4.35	4.29	2.35	3	2.98	4.74	3.94	3.06	1.69
Total current liabilities	3.02	5.28	5.26	3.45	3.79	3.75	5.96	4.71	3.76	2.6
Long-term debt								0.3	0.28	0.23
Lease liabilities			0	0.38	0.34	0.4	0.34	0.3	0.28	0.23
Other non-current liabilities		5.79	2.44	2.24	2	1.68	1.26	0.7	0
Total liabilities	6.95	14.6	10.8	8.69	8.92	8.5	9.62	7.15	5.11	3.27
Total debt		0	0	0	0	0	0	0	0	0
Paid-in capital	0.38	0.81	0.12	0.02	0.12	0.84	0.25	0.59	0	0
Retained earnings	81.1	85.6	100	111	111	115	126	138	129	129
Shareholders' equity	69.2	78.1	89	101	103	107	114	128	117	119
Total equity	69.2	78.1	89	101	103	107	114	128	117	119
Total liabilities and equity	76.2	92.7	99.8	110	112	116	124	135	123	123
Shares outstanding	3.71	0	0	3.72	3.64	3.66	3.63	3.63	3.34	3.19

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	12.1	8.51	18.6	14.7	10.8	14.8	16.5	16.6	13.9	11.3
Depreciation and amortization	0.61	0.66	0.77	0.7	0.66	0.64	0.61	0.62	0.73	0.83
Stock-based compensation	0.09	0.13	0.06	0.11	0.16	0.17	0.18	0.23	0.26	0.37
Deferred income tax	-0.48	-0.66	-0.33	-0.4	-0.03	-0.09	-0.4	-0.62	-0.34	-0.61
Change in receivables	-0.3	-0.24	-0.5	-0.74	0.62	-1.09	-0.51	2.27	-0.84	0.34
Change in inventory	0.36	-0.47	-0.24	-1.69	0.92	-0.49	-2.35	-0.67	0.59	1.2
Change in payables	0.29	0.01	0.05	0.11	-0.31	-0.02	0.46	-0.46	-0.07	0.21
Cash from operations	14.5	16.9	16.8	17.1	20.1	21.2	21.1	22.3	14.8	14.7
Capital expenditures	-3.29	-1.6	-0.4	-0.54	-0.86	-0.55	-0.81	-0.64	-0.23	-0.37
Cash from investing	-3.3	-1.6	0.53	-21.5	-0.86	-0.55	-0.82	-0.64	-0.21	-0.37
Stock issued	0.38	0.3	0.45	0.28	0.36	0.56	0.17	0.12	0.39	0
Share buybacks		0	-1.21	-0.4	-6.98	0	-2.5	0	-20	-8.36
Dividends paid	-3.92	-2.96	-4.03	-4.11	-4.12	-11.5	-3.16	-4.28	-4.26	-3.98
Cash from financing	-6.34	-2.65	-4.78	-4.23	-10.7	-10.9	-5.48	-4.17	-23.8	-12.3
Exchange rate effect	-1.87	0.92	-1.35	0.39	0.26	-0.36	-0.77	0.34	-0.68	0.8
Net change in cash	3.02	13.6	11.2	-8.33	8.8	9.38	14.1	17.8	-9.89	2.78
Free cash flow	11.2	15.3	16.4	16.5	19.3	20.7	20.3	21.6	14.6	14.3
Interest paid	0	0	0	0	0	0	0	0	0	0
Income taxes paid	4.85	5.15	4.85	5.3	3.19	4.62	4.97	4.83	4.64	4

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $74.18 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	57.9%	Gross profit / revenue.
Operating margin	28.4%	Operating income / revenue.
EBITDA margin	30.8%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	35.7%	Pre-tax income / revenue.
Net margin	29.0%	Net income / revenue.
FCF margin	31.7%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	32.8%	Cash from operations / revenue.
Effective tax rate	18.6%	Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)	8.6%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	8.4%	Net income / average total assets.
Return on invested capital (ROIC)	24.1%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue	1.9%	Research and development expense / revenue.
Stock-based pay / revenue	1.1%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	1.1%	Capital expenditures / revenue.
D&A / revenue	2.3%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	-5.8%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	-9.7%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	-1.8%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	-8.9%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	-11.9%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	-2.9%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income growth, 1y	-16.1%	Operating income vs the same period a year earlier. Only from a positive base.
Operating income CAGR, 3y	-16.8%	Compound annual growth of operating income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating income CAGR, 5y	-3.6%	Compound annual growth of operating income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EBITDA growth, 1y	-14.6%	EBITDA vs the same period a year earlier. Only from a positive base.
EBITDA CAGR, 3y	-15.7%	Compound annual growth of ebitda over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EBITDA CAGR, 5y	-3.2%	Compound annual growth of ebitda over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Net income growth, 1y	-18.7%	Net income vs the same period a year earlier. Only from a positive base.
Net income CAGR, 3y	-11.8%	Compound annual growth of net income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Net income CAGR, 5y	0.9%	Compound annual growth of net income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EPS growth, 1y	-12.1%	EPS vs the same period a year earlier. Only from a positive base.
EPS CAGR, 3y	-8.3%	Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EPS CAGR, 5y	3.4%	Compound annual growth of eps over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y	-0.9%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	-11.4%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow CAGR, 5y	-6.1%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Free cash flow growth, 1y	-1.9%	Free cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow CAGR, 3y	-11.0%	Compound annual growth of free cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Free cash flow CAGR, 5y	-5.8%	Compound annual growth of free cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	1.6%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	1.4%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	3.0%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	0.0%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-0.4%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	1.9%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	-7.5%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	-3.8%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	-2.5%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	48.6x	Current assets / current liabilities.
Quick ratio	44.0x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	42.3x	(Cash + short-term investments) / current liabilities.
Debt / equity	0.00x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	0.2%	Total debt / total assets.
Liabilities / assets	2.0%	Total liabilities / total assets.
Net debt	-$87.3M	Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA	-7.86x	Net debt / EBITDA (twelve months), when EBITDA is positive.
Working capital	$98.6M	Current assets - current liabilities.
Goodwill and intangibles / assets	11.5%	(Goodwill + intangible assets) / total assets.
Tangible book value	$107.7M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.29x	Revenue / average total assets.
Fixed asset turnover	3.75x	Revenue / average property, plant and equipment.
Inventory turnover	1.69x	Cost of revenue / average inventory.
Days inventory	216 days	365 x average inventory / cost of revenue.
Receivables turnover	10.1x	Revenue / average receivables.
Days sales outstanding	36 days	365 x average receivables / revenue.
Days payables	21 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	231 days	Days inventory + days sales outstanding - days payables.
FCF conversion	109.2%	Free cash flow / net income, when net income is positive.
Capex / operating cash flow	3.4%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	$3.28	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$11.34	Revenue / diluted weighted shares.
FCF per share	$3.60	Free cash flow / diluted weighted shares.
Operating cash flow per share	$3.72	Cash from operations / diluted weighted shares.
Book value per share	$38.34	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$33.85	Tangible book value / shares outstanding.
Cash per share	$27.50	(Cash + short-term investments) / shares outstanding.
Payout ratio	37.6%	Dividends paid / net income, when net income is positive.
Dividends / FCF	34.4%	Dividends paid / free cash flow, when free cash flow is positive.
Buybacks / FCF	16.2%	Share buybacks / free cash flow, when free cash flow is positive.

Valuation

Metric	Value	How it is calculated
Market cap	$236.2M	Share price x shares outstanding.
Enterprise value	$148.8M	Market cap + total debt - cash - short-term investments.
P/E	22.5x	Market cap / net income. Only when net income is positive.
P/S	6.54x	Market cap / revenue.
P/B	1.94x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	2.19x	Market cap / tangible book value, when positive.
P/FCF	20.6x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	19.9x	Market cap / cash from operations, when positive.
EV/Sales	4.12x	Enterprise value / revenue.
EV/EBIT	14.5x	Enterprise value / operating income, when both are positive.
EV/EBITDA	13.4x	Enterprise value / EBITDA, when both are positive.
EV/FCF	13.0x	Enterprise value / free cash flow, when both are positive.
FCF yield	4.8%	Free cash flow / market cap.
Earnings yield	4.4%	Net income / market cap (the inverse of P/E).
Dividend yield	1.7%	Dividends paid over the period / market cap.
Shareholder yield	2.5%	(Dividends paid + share buybacks) / market cap.

What was UTAH MEDICAL PRODUCTS INC's revenue in fiscal 2025?

UTAH MEDICAL PRODUCTS INC reported revenue of $38.5M for fiscal 2025, 5.8% lower than the year before.

Was UTAH MEDICAL PRODUCTS INC profitable in fiscal 2025?

Yes. Net income was $11.3M, a net margin of 29.3%.

How much free cash flow did UTAH MEDICAL PRODUCTS INC generate in fiscal 2025?

Cash from operations of $14.7M minus capital expenditures of $371.0K left free cash flow of $14.3M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to UTAH MEDICAL PRODUCTS INC